Clinical Trial: Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults

U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07688369) titled 'Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults' on June 19.

Brief Summary: The primary purpose of this study is to test a new experimental recombinant Poliomyelitis vaccine (rPV) in comparison to the commercially available inactivated poliovirus vaccine. The design of the study is double-blinded, randomised and active controlled. The active controlled product is considered the commercially available vaccine (IPOL).

Study Start Date: July, 2026

Study Type: INTERVENTIONAL

Condition: Polio Immunity

Intervention: BIOLOGICAL: Recombinant Poliomyelitis Vaccine ...